2/3/2022 1:20:50 AM
Takeda 9-month Reported EPS 154 Yen; Core EPS 333 Yen
1/31/2022 9:05:34 AM
Takeda:FDA Oks Prophylactic Treatment With VONVENDI For Adult Patients Living With Severe Type 3 Von Willebrand Disease
12/2/2021 9:54:52 AM
Takeda's LIVTENCITY Available For Individuals Ages 12 Yrs And Older With Post-Transplant CMV Infection/Disease In US
11/17/2021 8:17:13 AM
Canadian Blood Services Awards Takeda Canada Three-Year Tender For Hemophilia Treatment ADYNOVATE
11/4/2021 9:24:32 AM
Takeda Recommends Common-sense Policy Reforms
10/28/2021 2:05:46 AM
Takeda H1 Reported EPS 117 Yen Yen; Core EPS 214 Yen
10/13/2021 8:04:17 AM
BioLife Plasma Services Announces Opening Of New Plasma Center In Worcester, MA
9/30/2021 4:21:43 AM
Takeda And JCR Pharma Announce Collaboration And License Agreement To Commercialize JR-141 For Hunter Syndrome
9/21/2021 8:04:37 AM
Mirum Pharma And Takeda Enter Licensing Deal To Develop Maralixibat For Rare Pediatric Liver Diseases In Japan